文献速递妇科

维利帕尼联合贝伐珠单抗及铂类化疗一线治疗卵巢癌的I期研究

A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
PubMed 文献 · Gynecol Oncol · 2019-11-07

该I期研究评估了维利帕尼联合贝伐珠单抗及三种化疗方案(两种静脉、一种腹腔)一线治疗上皮性卵巢、腹膜或输卵管癌的最大耐受剂量和可行剂量。研究采用3+3剂量递增设计,纳入424例可评估患者,确定了各方案联合维利帕尼的可行剂量,并发现持续与间歇给药在疗效上无明显差异。

要点

  • 方案1c、2c、2i和3c的可行剂量均为维利帕尼150 mg口服每日两次。
  • 方案1i和3i的可行剂量分别推高至250 mg和300 mg口服每日两次。
  • 持续与间歇给药在疗效上无明显差异,间歇给药达到的更高剂量可能并非必需。

核心结论

  • 方案1c、2c、2i和3c的可行剂量为维利帕尼150 mg口服每日两次。
  • 方案1i和3i的可行剂量分别推高至250 mg和300 mg口服每日两次。
  • 持续与间歇给药在疗效上无明显差异,提示间歇给药达到的更高剂量可能并非必需。

研究设计与样本

  • I期3+3剂量递增研究,评估第1-2周期剂量限制性毒性,当<2/6例患者出现剂量限制性毒性时扩展至4周期评估可行性。
  • 研究于2009年10月开放,2016年8月关闭,纳入未经治疗、II-IV期上皮性卵巢、腹膜或输卵管癌患者。
  • 维利帕尼在6周期化疗期间持续(第1-21天)或间歇(第-2至5天)加入。
  • 评估三种化疗骨架:两种静脉方案(每3周一次和每周一次)和一种腹腔方案,均包含贝伐珠单抗并作为维持治疗至22周期。
  • 共424例接受治疗患者的剂量评估可用。

主要发现

  • 方案1(每3周一次)持续给药(Reg1c)的最大耐受剂量为维利帕尼250 mg每日两次,可行剂量为150 mg每日两次。
  • 方案1间歇给药(Reg1i)的最大耐受剂量和可行剂量分别为400 mg和250 mg每日两次。
  • 方案2持续给药(Reg2c,每周紫杉醇)的最大耐受剂量和可行剂量均为150 mg每日两次。
  • 方案2间歇给药(Reg2i)的最大耐受剂量和可行剂量分别为250 mg和150 mg每日两次。
  • 方案3持续给药(Reg3c,腹腔)的最大耐受剂量和可行剂量均为150 mg每日两次;方案3间歇给药(Reg3i,腹腔)的最大耐受剂量和可行剂量分别为400 mg和300 mg每日两次。

关键数值与推荐

  • 方案1c、2c、2i和3c的可行剂量为维利帕尼150 mg口服每日两次。
  • 方案1i和3i的可行剂量分别为维利帕尼250 mg和300 mg口服每日两次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improvements in disease free survival for epithelial ovarian, peritoneal or fallopian tube cancer (EOC) will only come with improved primary therapy. Incorporation of poly-ADP-ribose inhibitors (PARPi) in the frontline setting may represent one strategy. This study sought to determine the maximum tolerated and feasible doses of the PARPi veliparib in combination with chemotherapy for EOC. METHODS: A phase I, 3 + 3 dose escalation evaluated dose-limiting toxicities (DLTs) in cycles 1-2. Once <2/6 patients experienced a DLT, that dose level expanded to evaluate feasibility over 4 cycles. This study opened 10/2009 and closed 8/2016. Eligible patients had untreated, stage II-IV EOC. Veliparib was added either continuous (day 1-21) or intermittent (day - 2 to 5) during 6 cycles of chemotherapy. Three chemotherapy backbones were evaluated (2 intravenous (q3week and weekly) and 1 intraperitoneal (IP)) all inclusive of bevacizumab with and as maintenance to 22 cycles. FINDINGS: Dose evaluations for 424 treated patients were available. Regimen 1 (q3 week), continuous (Reg1c) the maximum tolerated dose (MTD) was 250 mg veliparib BID and feasible dose was 150 mg BID. For regimen 1, intermittent (Reg1i) the MTD and feasible dose were 400 and 250 mg BID. For Reg2c (weekly paclitaxel) the MTD and feasible dose were 150 mg BID. For Reg2i the MTD and feasible dose were 250 and 150 mg BID. For Reg3c (IP) the MTD and feasible dose were 150 mg BID and for Reg3i (IP), the MTD and feasible dose were 400 mg and 300 mg BID. INTERPRETATION: The feasible dose for Reg1c, 2c, 2i and 3c was 150 mg po BID. For Reg1i and 3i the dose was pushed to 250 and 300 mg po BID respectively. There is no apparent difference in efficacy between continuous and intermittent dosing indicating that the higher doses achieved in intermittent dosing may not be needed. (NCT00989651). FUNDING: National Cancer Institute.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moore KN, Miller A, Bell-McGuinn KM, et al. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2019. PMID: 31708167. doi:10.1016/j.ygyno.2019.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。